Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This month the MRC Weatherall Institute of Molecular Medicine (WIMM) hosted the annual Regional Breast Cancer Academic Day, an event that brings together breast cancer teams from across the Thames Valley region. This year’s symposium involved the participation of over 70 attendees, including nurses, clinical trial managers, researchers and doctors.

In addition to the usual mix of internal and external speakers, this year's event was also an opportunity to highlight the contributions of Professor Adrian Harris, one of the organisers of the event. Professor Harris founded the Oxfordshire Breast Clinic in 1989. The event marked his official retirement from the clinic and from the National Health Service. Professor Harris will continue to lead a research group in the Department of Oncology.

The Harris group works on tumour angiogenesis and the role of Notch signalling, and hypoxia biology and its regulation. The ultimate aim of the research programme is to develop ways to improve the treatment of breast cancer and other tumour types, by blocking the blood supply to tumours. Professor Harris' group is one of the several research teams from the Department of Oncology within the WIMM, whose research focuses on cancer research. The Regional Breast Cancer Academic Day was sponsored by Eisai, Pierre Fabre, Novartis, Pfizer and Synthon.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.